Coriolus versicolor to Treat Cancer - Quick Reference Sheet

Coriolus versicolor to Treat Cancer

Created on 07/27/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Turkey tail mushroom extracts have been used for decades alongside surgery, chemotherapy, and radiotherapy to support the body's own defenses during cancer treatment. The most consistent signal is modestly longer survival when added after surgery for stomach and bowel cancer. It is well tolerated, mainly causing mild digestive effects, but may concern those on immune-suppressing drugs. (Full Review)

Protocol

Dose
3 g daily
Standard adjuvant dose; titrate up to 6–9 g/day as tolerated
Form
PSK / PSP extract
Standardized, beta-glucan–verified extract, not mycelium-on-grain
Timing
2–3 divided doses
Taken with meals across the day
Time to effect
Survival benefit
Months to years
Long-term outcome of sustained adjuvant use
Immune markers
Within weeks
Measurable immune-parameter changes

Benefits

Contraindications
  • Solid-organ transplant recipients on immunosuppression
  • Active autoimmune disease
  • Known mushroom allergy
  • Pregnancy or breastfeeding
Key Interactions
  • Immunosuppressants (tacrolimus, cyclosporine)
  • Chemotherapy agents (tegafur-uracil, capecitabine)
  • Anticoagulants and antiplatelets (warfarin, apixaban, aspirin, clopidogrel)
  • Immunostimulant supplements (reishi, maitake, AHCC, echinacea, beta-glucans)

Risk & Side Effects

  • High:
  • Medium: Mild gastrointestinal effects
  • Low: Nail and skin hyperpigmentation; transient liver enzyme elevation
  • Speculative: Immune overstimulation in autoimmune disease or transplantation; allergic and hypersensitivity reactions

Monitoring

Marker Target Why
Complete blood count with differential Neutrophils and lymphocytes within the mid-normal range Tracks immune recovery and detects chemotherapy-related low counts
Liver enzymes (AST, ALT) Roughly 10–30 U/L Detects the rare transient enzyme elevation and monitors chemotherapy effects
Carcinoembryonic antigen (colorectal) Ideally below about 3 ng/mL in non-smokers Follows disease response and recurrence in colorectal cancer
Helper/killer T-cell ratio (CD4/CD8) Approximately 1.5–2.5 Reflects immune balance that cancer and chemotherapy tend to suppress

Cadence: Complete blood count and liver enzymes at baseline, then approximately every 4–12 weeks during active adjuvant treatment; tumor-marker and imaging follow-up aligned with the oncology team (commonly every 3–6 months, then every 6–12 months).

Qualitative Assessment

  • Energy levels and day-to-day fatigue
  • Appetite and maintenance of body weight
  • Tolerance of chemotherapy or radiotherapy (fewer dose delays or reductions)
  • General sense of well-being and functional capacity